Extensive research has investigated the potential therapeutic benefit of inhibiting sEH in various cardiovascular injury models such as ischemic heart diseases, arrythmias, hypertrophy and heart failure (Imig and Hammock, 2009; Oni-Orisan et al., 2014; Schunck et al., 2018). Here, EPHX2 is linked to coronary artery disorder.